Both in Pharmaceuticals
Ocular Therapeutix vs Supernus
Over the past year OCUL returned −34.5% and SUPN returned −50.5%; their daily moves had a correlation of 0.15.
OCUL −34.5% SUPN −50.5%Growth of $1, one year, split-adjusted
| Metric | OCUL | SUPN |
|---|---|---|
| Price | $7.14 | $28.21 |
| Market cap | $1.57B | $1.64B |
| Today | +4.69% | +0.21% |
| 1 month | −2.7% | −34.1% |
| 6 months | −26.5% | −45.2% |
| Year to date | −41.2% | −43.2% |
| 1 year | −37.4% | — |
| Revenue growth (YoY) | +0.1% | +18.0% |
| Gross margin | 85.1% | 88.1% |
| Net margin | −584.5% | 9.2% |
| P/E (TTM) | — | — |
| Price / sales | 30.1× | 1.9× |
| Net cash | $525.8M | $359.5M |
| Dividend yield | — | 28.82% |
| Volatility (60d) | 75.4% | 86.1% |
| Short % of float | 15.1% | 7.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).